-
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 27 locations
-
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
NCT04370587 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 9 locations
-
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
NCT05366478 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
A Clinical Study of T3011 in Subjects With Advanced Melanoma
NCT06214156 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 7 locations
-
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
NCT06839105 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 13 locations
-
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 76 locations
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 16 locations
-
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
NCT05077137 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT06413680 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 11 locations
-
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
NCT07600476 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 3 locations
-
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 9 locations
-
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT05746897 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
NCT07317505 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 6 locations
-
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 12 locations
-
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
NCT07376707 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
NCT07636785 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 10 locations
-
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
NCT07076550 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 4 locations
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
NCT06956690 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 14 locations
-
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 107 locations
-
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
NCT06636435 ·
Phase: Phase 1 ·
Ages: 2 Years and older ·
Sex: All (male and female) · 5 locations
-
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
NCT01638676 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
NCT06727630 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
NCT03829254 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 9 locations
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT05970497 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 15 locations
-
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
NCT05562791 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 7 locations
-
A Study of BI 3810944 in Patients With Advanced Cancer
NCT07224425 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 7 locations
-
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT04895709 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 94 locations
-
A Study of DEG6498 in Participants With Solid Tumors
NCT07244835 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 9 locations
-
A Study of DXC014 in Patients With Advanced Solid Tumors.
NCT07177937 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 5 locations
-
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 13 locations
-
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
NCT07106827 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
NCT07518043 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 7 locations
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
NCT05607095 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 36 locations
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
NCT05859074 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 7 locations
-
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 17 locations
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT06090266 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 4 locations
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT06362369 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 5 locations
-
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT02332668 ·
Phase: Phase 1, Phase 2 ·
Ages: 6 Months to 17 Years ·
Sex: All (male and female) · 16 locations
-
A Study of ST-1898 for Unresectable or Metastatic Melanoma
NCT06359860 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
A Study of TRK-950 in Patients With Advanced Solid Tumors
NCT05423262 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 10 locations
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
NCT06066138 ·
Phase: Phase 1 ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female) · 1 location
-
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 7 locations
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05592626 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 19 locations
-
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
NCT06880549 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 4 locations
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
NCT06805825 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 5 locations
-
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
NCT07749586 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 6 locations
-
A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma
NCT07086105 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 3 locations
-
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 48 locations
-
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 120 locations
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT05824975 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 22 locations
-
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 26 locations
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT05361174 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 11 locations
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
NCT06940739 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 5 locations
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 23 locations
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130 ·
Phase: Phase 1 ·
Ages: 16 Years and older ·
Sex: All (male and female) · 83 locations
-
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701 ·
Phase: Phase 1 ·
Ages: 16 Years and older ·
Sex: All (male and female) · 40 locations
-
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
NCT07099430 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 15 locations
-
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07027488 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
ACTengine® IMA203 Combined With mRNA-4203
NCT06946225 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 4 locations
-
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT03686124 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 21 locations
-
AMT-253 in Patients With Advanced Solid Tumours
NCT06209580 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
NCT07063875 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT02830724 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 72 Years ·
Sex: All (male and female) · 1 location
-
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
NCT02870244 ·
Phase: Phase 1 ·
Ages: 18 Years to 89 Years ·
Sex: All (male and female) · 1 location
-
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
NCT06942143 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
NCT07371663 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 3 locations
-
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
NCT05296564 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy
NCT07562841 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
NCT00722228 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
NCT04897321 ·
Phase: Phase 1 ·
Ages: Up to 21 Years ·
Sex: All (male and female) · 1 location
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
NCT04752826 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 25 locations
-
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
NCT06163820 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
NCT07410494 ·
Phase: Phase 1, Phase 2 ·
Ages: 8 Years to 85 Years ·
Sex: All (male and female) · 3 locations
-
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
NCT06961357 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Combination Immunotherapy Targeting Melanoma
NCT06739226 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
NCT07288112 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 8 locations
-
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
NCT06194929 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
NCT07627698 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
NCT07410676 ·
Phase: Phase 1, Phase 2 ·
Ages: No age limits stated ·
Sex: All (male and female) · 1 location
-
Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
NCT03685890 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 4 locations
-
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
NCT07136181 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 3 locations
-
FMT to Convert Response to Immunotherapy
NCT05251389 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT04038619 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
NCT05983237 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
NCT06265025 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 4 locations
-
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT04119024 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 3 locations
-
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
NCT06708663 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
NCT07281924 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT05039801 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
IDOV-Immune for Advanced Solid Tumors
NCT06910657 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 10 locations
-
IL-17 Blockade to Decrease irAEs (REPLAY)
NCT07237594 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT05896839 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 26 locations
-
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
NCT06240143 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 6 locations
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
NCT04697576 ·
Phase: Phase 1 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female) · 1 location
-
Intratumoral N17350 in Advanced Solid Tumors
NCT07339176 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 16 locations
-
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
NCT07718243 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer
NCT04729543 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female) · 13 locations
Showing 100 of 156 recruiting trials.